Gastroenterologie
a hepatologie

Noninvasive diagnostics in NAFLD

Karel Dvořák ^{Orcid.org  1}

+ Affiliation
¹ Oddělení gastroenterologie a hepatologie, Krajská nemocnice Liberec, a.s., Nemocnice Liberec

Summary

Non-alcoholic fatty liver disease (NAFLD) represents one of the most common chronic liver diseases affecting more than 25% of the population. The majority of patients have simple steatosis, but some develop liver cirrhosis with its complications. In such a prevalent condition there is a need for non-invasive diagnostic methods allowing stratification of patients without liver biopsy. This summary lists the current options of non-invasive diagnostics of NAFLD.

Keywords

elastography, fibrosis, non-alcoholic fatty liver disease, non-invasive diagnosis

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Literature

1. Cholongitas E, Senzolo M, Standish R et al. A systematic review of the quality of liver biopsy specimens. Am J Clin Pathol 2006; 125(5): 710–721.
2. Ratziu V, Charlotte F, Heurtier A et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128(7): 1898–1906.
3. Hernaez R, Lazo M, Bonekamp S et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta‑analysis. Hepatology 2011; 54(3): 1082–1090. doi: 10.1002/hep.24452.
4. Lee SS, Park SH, Kim HJ et al. Non‑invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol 2010; 52(4): 579–585. doi: 10.1016/j.jhep.2010.01.008.
5. Wong VW, Wong GL, Choi PC et al. Disease progression of non‑alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59(7): 969–974. doi: 10.1136/gut.2009.205088.
6. Ekstedt M, Franzén LE, Mathiesen UL et al. Long‑term follow‑up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44(4): 865–873.
7. Neuschwander‑Tetri BA, Clark JM, Bass NM et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010; 52(3): 913–924. doi: 10.1002/hep.23784.
8. Bedogni G, Bellentani S, Miglioli L et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33.
9. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8(3): 521–533.
10. Mofrad P, Contos MJ, Haque M et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37(6): 1286–1292.
11. Hui AY, Wong VW, Chan HL et al. Histological progression of non‑alcoholic fatty liver disease in Chinese patients. Aliment Pharmacol Ther 2005; 21(4): 407–413.
12. Haring R, Wallaschofski H, Nauck M et al. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma‑glutamyl transpeptidase levels. Hepatology 2009; 50(5): 1403–1411. doi: 10.1002/hep.23135.
13. Hui JM, Hodge A, Farrell GC et al. Beyond insulin resistance in NASH: TNF‑alpha or adiponectin? Hepatology 2004; 40(1): 46–54.
14. Jarrar MH, Baranova A, Collantes R et al. Adipokines and cytokines in non‑alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 27(5): 412–421.
15. Musso G, Gambino R, Cassader M et al. Meta‑analysis: natural history of non‑alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non‑invasive tests for liver disease severity. Ann Med 2011; 43(8): 617–649. doi: 10.3109/07853890.2010.518623.
16. Dvorak K, Stritesky J, Petrtyl J et al. Use of non‑invasive parameters of non‑alcoholic steatohepatitis and liver fibrosis in daily practice – an exploratory case‑control study. PLoS One 2014; 9(10): e111551. doi: 10.1371/journal.pone.0111551.
17. Angulo P, Keach JC, Batts KP et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30(6): 1356–1362.
18. Machado MV, Cortez‑Pinto H. Non‑invasive diagnosis of non‑alcoholic fatty liver disease. A critical appraisal. J Hepatol 2013; 58(5): 1007–1019. doi: 10.1016/j.jhep.2012.11.021.
19. Ratziu V, Giral P, Charlotte F et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118(6): 1117–1123.
20. Harrison SA, Oliver D, Arnold HL et al.Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57(10): 1441–1447. doi: 10.1136/gut.2007.146019.
21. Guha IN, Parkes J, Roderick P et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47(2): 455–460.
22. Angulo P, Hui JM, Marchesini G et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45(4): 846–854.
23. Wong VW, Vergniol J, Wong GL et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51(2): 454–462. doi: 10.1002/hep.23312.
24. Huwart L, Sempoux C, Vicaut E et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 2008; 135(1): 32–40. doi: 10.1053/j.gastro.2008.03.076.